4D Molecular Therapeutics posted Q2 2025 collaboration and license revenue of $15K, with R&D and G&A expenses totaling $59.47M. Net loss was $54.66M (−$0.98 EPS) compared to $34.95M in Q2 2024. The company ended the quarter with $417.03M in cash, cash equivalents, and marketable securities, projecting its runway into 2028.

4D Molecular Therapeutics, Inc. reported a net loss of $47.972 million for the first quarter of 2025, an increase from $32.401 million in the same period last year. This was primarily driven by a significant increase in research and development expenses, which rose by 46% to $40.699 million. The company's total operating expenses increased by 41%, while revenue remained immaterial.

4D Molecular Therapeutics reported a net loss of $160.9 million for the full year 2024, an increase from $100.8 million in 2023. Research and development expenses significantly increased to $141.3 million, driven by the progression of clinical trials. The company ended 2024 with $505 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2028.

4DMT reported positive interim data for 4D-150 in wet AMD and is on track with the 4FRONT Phase 3 program. The company's cash, cash equivalents, and marketable securities were $551 million as of September 30, 2024, expected to fund planned operations at least into H1 2027.

4DMT reported second quarter 2024 financial results, highlighting positive interim results from the Phase 2 PRISM clinical trial for 4D-150 in wet AMD, strengthened senior leadership, and $578 million in cash and equivalents as of June 30, 2024.

4DMT reported a net loss of $32.4 million for Q1 2024, compared to a net loss of $28.7 million for Q1 2023. Cash, cash equivalents, and marketable securities were $589 million as of March 31, 2024, expected to fund operations into H1 2027.

4D Molecular Therapeutics reported a transformative year in 2023, marked by significant progress in its product pipeline and platform across multiple therapeutic areas. The company highlighted positive interim data from the Phase 2 PRISM study of 4D-150 in wet AMD, advancements in clinical trials for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease, and strategic agreements with Astellas Pharma and Arbor Biotechnologies. 4DMT's cash position was strengthened by a completed public follow-on offering, extending its operational runway into the first half of 2027.

4DMT reported a net loss of $10.3 million for Q3 2023, compared to a net loss of $25.7 million for Q3 2022. Cash and cash equivalents were approximately $320 million as of September 30, 2023, and the company expects this to fund operations into the first half of 2026.

4DMT reported positive interim data from clinical trials for 4D-150 and 4D-710, completed target enrollment for the Phase 2 PRISM clinical trial, and entered a license agreement with Astellas Pharma, receiving $20 million upfront. They closed the quarter with $310 million in cash, cash equivalents, and marketable securities.

4D Molecular Therapeutics reported positive interim data from the PRISM clinical trial, acquired rights to sCFH, and closed an upsized public offering, with cash expected to fund operations into the first half of 2026.

4DMT reported full year 2022 financial results, highlighting the validation of their Therapeutic Vector Evolution platform and progress in their clinical pipeline. The company's cash position is expected to fund operations into the first half of 2025.

4D Molecular Therapeutics reported third quarter 2022 financial results. The company's cash, cash equivalents and marketable securities were $239 million as of September 30, 2022, which is expected to fund operations into the first half of 2025. Total revenue for the quarter was $0.5 million and net loss was $25.7 million.

4D Molecular Therapeutics reported second quarter 2022 financial results. The company's cash, cash equivalents and marketable securities were $261.6 million as of June 30, 2022, expected to fund operations into the first half of 2025. Total revenue for the quarter was $0.2 million, and the net loss was $28.1 million.

4D Molecular Therapeutics reported first quarter 2022 financial results, including revenue of $1.2 million and a net loss of $26.3 million. The company highlighted progress in its clinical programs and the completion of its commercial-scale GMP manufacturing facility.

4D Molecular Therapeutics reported full year 2021 financial results, highlighting clinical data updates on multiple programs, advancement of additional programs into clinical development, and initiation of GMP manufacturing facility expansion. The company's cash, cash equivalents, and investments of $315 million are expected to fund operations into the second half of 2024.

4D Molecular Therapeutics reported Q3 2021 financial results, including total revenue of $1.4 million and a net loss of $22.2 million. The company highlighted clinical data updates on three programs and the clearance of IND applications for two product candidates. A public offering of common stock resulted in net proceeds of approximately $111 million, strengthening the balance sheet.

4D Molecular Therapeutics reported a total revenue of $14.6 million for the quarter ended June 30, 2021, compared to $3.6 million for the quarter ended June 30, 2020. Net loss was $7.6 million for the quarter ended June 30, 2021, as compared to $15.2 million for the quarter ended June 30, 2020. Cash and cash equivalents were $243.7 million as of June 30, 2021.

4D Molecular Therapeutics reported a revenue of $2.0 million and a net loss of $16.4 million for the quarter ended March 31, 2021. The company's cash and cash equivalents were $259.9 million as of March 31, 2021, expected to fund operations into mid-2023.